aTyr Pharma, Inc.
ATYR
$0.83
$0.011.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -100.00% | -- | |||
| Cost of Revenue | -50.79% | 43.85% | |||
| Gross Profit | 50.36% | -42.62% | |||
| SG&A Expenses | -18.73% | -2.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -45.07% | 32.60% | |||
| Operating Income | 44.68% | -31.66% | |||
| Income Before Tax | 45.76% | -31.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 45.76% | -31.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -50.00% | 100.00% | |||
| Net Income | 45.76% | -31.81% | |||
| EBIT | 44.68% | -31.66% | |||
| EBITDA | 44.96% | -31.93% | |||
| EPS Basic | 46.23% | -22.29% | |||
| Normalized Basic EPS | 46.26% | -22.30% | |||
| EPS Diluted | 46.23% | -22.29% | |||
| Normalized Diluted EPS | 46.26% | -22.30% | |||
| Average Basic Shares Outstanding | 0.88% | 7.80% | |||
| Average Diluted Shares Outstanding | 0.88% | 7.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||